Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

BACKGROUND: It is unknown whether the outcomes of second-line pemetrexed-carboplatin chemotherapy administered after progression on gefitinib are dependent on type of EGFR mutation present at baseline. METHOD: Adult non-small-cell lung cancer patients, with exon 19 deletion or exon 21 L858R mutation...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Chemother Res Pract
Hlavní autoři: Joshi, Amit, Noronha, Vanita, Patil, Vijay M., Chougule, Anuradha, Bhattacharjee, Atanu, Kumar, Rajiv, Goud, Supriya, More, Sucheta, Ramaswamy, Anant, Karpe, Ashay, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Médium: Artigo
Jazyk:Inglês
Vydáno: Hindawi 2017
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5672602/
https://ncbi.nlm.nih.gov/pubmed/29201462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/8196434
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky